Next-Gen Delivery System Market 2026: How Pharma Giants and Biotechs Are Changing Treatment Forever!

Drug delivery used to be simple. A tablet dissolves in the stomach or an injection releases medicine into the bloodstream. But human biology is far more complex than that.

Modern therapies such as biologics, gene therapies, and RNA-based treatments require highly specialized delivery methods. Without proper delivery, these therapies may degrade before reaching their target.

Next-gen delivery system aim to solve this issue by improving stability, targeting, and control. Many of these systems can release drugs gradually or transport them directly to specific cells.

As a result, treatments are becoming safer and more effective.

Technologies That Are Changing the Game

Several innovative technologies are driving this transformation in drug delivery. These platforms combine biotechnology, materials science, and engineering.

Some of the most notable technologies include:

• Lipid Nanoparticles (LNPs) that protect fragile genetic medicines and deliver them into cells.

• Microneedle patches that allow painless vaccine delivery through the skin.

• Smart insulin pumps that automatically adjust insulin doses.

• Implant-based drug systems that release medication over months instead of days.

These technologies are not theoretical concepts anymore. Many are already entering clinical practice and transforming patient care.

Companies Pushing the Innovation Frontier

Download Free Sample: https://www.towardshealthcare.com/download-sample/5758

A growing group of biotechnology and medical device companies is working to redefine drug delivery.

For instance, Alnylam Pharmaceuticals is advancing lipid nanoparticle and GalNAc conjugate technologies designed to deliver RNA therapies with higher precision. These platforms have opened new possibilities in gene-silencing medicines.

Medical device innovator Insulet Corporation has introduced the Omnipod 5 system, a tubeless insulin delivery platform that integrates with continuous glucose monitoring. This system helps automate diabetes management and reduce the burden on patients.

Meanwhile, Halozyme Therapeutics has developed ENHANZE technology, which improves the absorption of injected medicines by temporarily modifying tissue under the skin. This allows certain therapies to be delivered more conveniently.

Other companies are focusing on equally groundbreaking innovations.

• Ionis Pharmaceuticals has created LICA technology, which enhances the delivery efficiency of antisense drugs.

• Vaxxas is developing the HD-MAP microneedle patch for vaccine delivery without traditional needles.

• MannKind Corporation has pioneered Technosphere technology that enables inhalable medicines.

• PolyPid is working on the PLEX platform designed for long-term localized drug release.

Together, these innovations show that drug delivery is becoming a key competitive frontier in the pharmaceutical industry.

When Pharma Giants Enter the Race

Large pharmaceutical companies are also recognizing the importance of delivery technologies.

Industry leaders such as Roche, Pfizer, Novartis, Johnson & Johnson, AstraZeneca, and Sanofi are actively exploring advanced delivery solutions. Their focus is not just on new drugs but also on optimizing how these drugs interact with the human body.

Improved delivery systems can extend the life of existing drugs, enhance treatment outcomes, and improve patient adherence.

For pharmaceutical companies, this represents a strategic shift. Instead of focusing only on drug molecules, they are now investing in the entire therapeutic ecosystem.

Partnerships That Accelerate Discovery

Collaboration is becoming a defining trend in this market.

Biotechnology startups often bring cutting-edge technology platforms, while established pharmaceutical companies contribute clinical expertise and global development capabilities.

One example emerged in 2025 when biotechnology company Bexorg collaborated with Biohaven to advance research in neurological therapies. Their technology enables preclinical testing of treatments on metabolically active human brain tissue.

This approach allows researchers to better understand drug safety, pharmacokinetics, and pharmacodynamics before clinical trials begin.

Another notable collaboration took place between Taiho Pharmaceutical and biotechnology firm Araris. The partnership focuses on using the AraLinQ technology platform to support next-generation antibody-drug conjugate discovery.

Such collaborations show how innovation often grows faster when expertise from multiple fields comes together.

New Breakthroughs in 2025

The year 2025 saw several milestones in drug delivery innovation.

Medical device company Neurent Medical received regulatory clearance for its next-generation Neuromark system designed to treat chronic rhinitis. The system offers a non-surgical solution for patients suffering from persistent nasal inflammation.

Another research breakthrough came from a collaboration between scientists in India, Saudi Arabia, and the United Arab Emirates. The team developed a novel drug delivery system for colon cancer using cross-linked nanoparticles derived from natural resin known as mastic gum.

This approach aims to improve the targeting of cancer therapies within the digestive system.

Such breakthroughs highlight how research in this field is expanding globally.

Why Drug Delivery Matters More Than Ever

The pharmaceutical landscape is evolving rapidly. New therapeutic approaches like gene therapy, mRNA vaccines, and personalized medicine require delivery methods that did not exist a decade ago.

Without effective delivery, even the most advanced drug molecules may fail to produce desired clinical outcomes.

Modern delivery systems help solve several key challenges:

• They protect fragile drug molecules from degradation.

• They target specific tissues or cells, reducing side effects.

• They improve patient convenience, which increases treatment adherence.

In some cases, improved delivery methods can completely transform how a therapy works.

Patients at the Center of Innovation

Another major reason for the rise of next-generation delivery systems is patient experience.

Many traditional treatments require frequent injections or hospital visits. New delivery technologies aim to make treatments less invasive and more accessible.

Microneedle patches, wearable pumps, inhalable medicines, and long-acting implants allow patients to manage conditions with minimal disruption to daily life.

For people living with chronic illnesses such as diabetes, respiratory diseases, or autoimmune disorders, these innovations can significantly improve quality of life.

Healthcare is gradually moving toward patient-centric treatment models, and delivery technology plays a crucial role in that shift.

Access our exclusive, data-rich dashboard dedicated to the therapeutics area sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

Checkout the Market Report Now at: https://www.towardshealthcare.com/checkout/5758

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region – +44 778 256 0738

North America Region – +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium

About the Author

sanskruti sathe

Administrator

View All Posts